JW HoldingsJW홀딩스

JW Holdings trades near book value and a low earnings multiple, with TTM profit still solid but shrinking from its 2024 peak.

JW Holdings is a Korean holding company whose subsidiaries make pharmaceutical raw materials, finished drugs and medical devices, with income from dividends, royalties and management services. On trailing numbers to H1 2026 it reports revenue of ₩1.01T, operating income of ₩190B and net income of ₩84B, with a 5.4% dividend yield at a price of ₩3,945. The data also shows borrowings of ₩147B against cash of ₩75B.

What stands out

• Net income for 2025 was ₩58B, below ₩63B in 2024, even though 2025 revenue rose 9.2%.
• Trailing operating margin is 18.8%, up from 17.3% in 2025, and trailing free cash flow is ₩178B.
• Valuation metrics are low: P/E about 3.5, P/B about 1.0, P/S about 0.3, and the DCF base value is ₩25,947, well above the current price.
• The share price is down 7.7% over one month but up 19.5% over one year, sitting between its 52-week low of ₩3,195 and high of ₩4,720.
• Recent filings include a change in largest shareholder's holdings, several 5%+ holding reports and a sale of shares in another company; no news headlines were supplied.

What to watch

• The next filing with full-year or quarterly results, to see whether the margin gains hold.
• The details of the largest shareholder's holding change and the share sale, which the data does not explain.
• The DCF bear case of ₩14,164 and the leverage level (liabilities at 97.6% of equity), which the data flags as risks to the valuation.